HNGZ.Y Stock Overview
Provides contract research organization services in the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Hangzhou Tigermed Consulting Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.14 |
| 52 Week High | CN¥4.40 |
| 52 Week Low | CN¥4.14 |
| Beta | 0.86 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| HNGZ.Y | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | -2.7% |
| 1Y | n/a | -5.5% | 23.4% |
Return vs Industry: Insufficient data to determine how HNGZ.Y performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how HNGZ.Y performed against the US Market.
Price Volatility
| HNGZ.Y volatility | |
|---|---|
| HNGZ.Y Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: HNGZ.Y's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HNGZ.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 9,348 | Xiaochun Cao | www.tigermedgrp.com |
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.
Hangzhou Tigermed Consulting Co., Ltd Fundamentals Summary
| HNGZ.Y fundamental statistics | |
|---|---|
| Market cap | US$6.88b |
| Earnings (TTM) | US$131.77m |
| Revenue (TTM) | US$934.84m |
56.2x
P/E Ratio7.9x
P/S RatioIs HNGZ.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNGZ.Y income statement (TTM) | |
|---|---|
| Revenue | CN¥6.80b |
| Cost of Revenue | CN¥4.27b |
| Gross Profit | CN¥2.54b |
| Other Expenses | CN¥1.58b |
| Earnings | CN¥958.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.11 |
| Gross Margin | 37.29% |
| Net Profit Margin | 14.10% |
| Debt/Equity Ratio | 15.2% |
How did HNGZ.Y perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield51%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/15 21:30 |
| End of Day Share Price | 2024/09/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hangzhou Tigermed Consulting Co., Ltd is covered by 39 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Luo | BOCI Research Ltd. |
| Linda Lu | BOCI Research Ltd. |
| Bo Li | BofA Global Research |